impact factor
logo
 

One year in review

 

One year in review 2022: systemic lupus erythematosus


1, 2, 3, 4, 5, 6, 7

 

  1. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy. dinazucchi@hotmail.it
  2. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  3. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  4. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  5. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  6. Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Ferrara, Italy.
  7. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.

CER15480
2022 Vol.40, N°1
PI 0004, PF 0014
One year in review

Free to view
(click on article PDF icon to read the article)

PMID: 35088691 [PubMed]

Received: 13/01/2022
Accepted : 17/01/2022
In Press: 28/01/2022
Published: 28/01/2022

Abstract

Systemic lupus erythematosus (SLE) is a chronic multisystem auto-immune disease with extremely varied clinical manifestations and a complex pathogenesis. New insights in SLE about pathogenetic pathways, biomarkers, and data on clinical manifestations are progressively emerging, and new drugs and new therapeutic strategies have been proposed to improve the control of disease activity. Thus, this review is aimed to summarise the most relevant data about SLE emerged during 2021, following the previous annual review of this series.

DOI: https://doi.org/10.55563/clinexprheumatol/nolysy

Rheumatology Article